Clinical Laserthermia Systems signs LOI with HALO Precision Diagnostics for TRANBERG Thermal Therapy System
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that their US subsidiary CLS Americas has signed a Letter of Intent (LOI) with HALO Precision Diagnostics, Inc. (HALO) for evaluation of safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy System.
HALO will conduct an initial post-market study treating up to twenty-five (25) patients at one or more of its HALO Ambulatory Surgery Centers in the US to evaluate the safety and short term efficacy of CLS’s TRANBERG Thermal Therapy System for treating low-to-medium risk prostate cancer patients with FLA therapy outside of a hospital setting. Upon completion of its evaluation, HALO and CLS Americas will enter discussions regarding HALO’s acquisition of TRANBERG Thermal Therapy System for use in some of its nationwide system of approximately 16 clinics.
“I’m very excited that CLS can start this important collaboration with HALO to bring CLS’s FLA treatment closer to the patients by offering treatment at local urology doctor’s offices and clinics,” says Dan J. Mogren, CEO of CLS. “CLS goal is to deliver TRANBERG Thermal Therapy Systems for safe and efficient treatments of prostate cancer and by bringing the treatment closer to the patient and treating them in an early stage, the quality of life of more patients can be preserved.”
In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men. Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 (0)70 590 11 40
E-mail: dan.mogren@clinicallaser.com
About HALO Precision Diagnostics
HALO Precision Diagnostics changes patient lives and outcomes through early detection of the leading causes of death with precision diagnostics. We accomplish this with a personalized diagnostic ensemble including advanced imaging, genomics, non-invasive liquid biomarkers, and community-based data at scale combined with deep learning algorithms. By optimizing all these solutions under the HALO Precision Diagnostics platform, we provide rapid, precise, actionable results to enable life-changing treatments by physicians for their patients.
For more information about HALO Precision Diagnostics, please visit the Company's website: https://www.halodx.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including Thermoguide™ Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se
For more information about CLS, please visit the Company's website: www.clinicallaser.se
This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-02-2023 18:15 CET.